A. Swarbrick

An experimental comparison of the Digital Spatial Profiling and Visium spatial transcriptomics technologies for cancer research

This study compares Digital Spatial Profiling and Visium spatial transcriptomics technologies for cancer research, finding differences in sensitivity, specificity, and application suitability.

snPATHO-seq: unlocking the FFPE archives for single nucleus RNA profiling

This paper introduces snPATHO-Seq, a method for high-quality single nucleus RNA sequencing from FFPE samples, showing improved sensitivity and accuracy compared to existing methods.

Integration of single-cell RNA and protein data identifies novel clinically-relevant lymphocyte phenotypes in breast cancers

The paper integrates single-cell RNA and protein data from breast cancer samples to identify novel lymphocyte phenotypes and their clinical relevance.

Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer

The paper shows that inhibiting lactate production in tumor cells suppresses PTEN/p53-deficient prostate cancer growth by activating macrophage phagocytosis.

STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological dysregulation of NKG2Dhi CD8 killer T cells

This study shows that STAT3 gain-of-function mutations in leukemia drive autoimmune pathology by causing NKG2Dhi CD8 T cell oligoclonal expansion and cytotoxic activity.

DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapy

This study uses DNA barcoding to track clonal evolution in breast cancer during metastasis and immunotherapy, finding ongoing immunoediting and identifying potential therapeutic targets.

Spatial Deconvolution of HER2-positive Breast Tumors Reveals Novel Intercellular Relationships

This study uses spatial transcriptomics to analyze HER2-positive breast tumors, revealing novel intercellular relationships and developing a model for tertiary lymphoid structures across tissues.

MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer.

This study evaluates MDM2 inhibition combined with endocrine therapy and CDK4/6 inhibition in ER-positive breast cancer, showing synergistic anti-tumor effects in resistant models.

Single-cell analysis reveals diverse stromal subsets associated with immune evasion in triple-negative breast cancer

This study identifies diverse stromal subsets in TNBC using single-cell RNA-seq and links them to immune evasion mechanisms and therapeutic targets.

Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis

This study shows that cryopreservation of human cancers preserves tumour heterogeneity for single-cell multi-omics analysis, with comparable results to fresh tissue.

Id proteins promote a cancer stem cell phenotype in triple negative breast cancer via negative regulation of Robo1

This study shows that Id proteins promote a cancer stem cell phenotype in triple negative breast cancer by negatively regulating Robo1, leading to Myc activation.

Targeting the Id1-Kif11-Aurka axis in triple negative breast cancer using combination therapy

This paper investigates how Id1 and Id3 maintain chemoresistant CSCs in TNBC by targeting Kif11 and Aurka, and explores combination therapy to enhance tumor debulking.

MicroRNAs as potential therapeutics to enhance chemosensitivity in advancedprostate cancer

This study identifies microRNA mimics that enhance taxane-induced apoptosis in CRPC cell lines, suggesting potential therapeutic use to improve chemosensitivity.

Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer

This study identifies Hedgehog signaling to cancer-associated fibroblasts as a driver of cancer stem cell plasticity and chemoresistance in TNBC, showing that targeting this pathway with smoothened inhibitors improves survival in preclinical models and clinical trials.